{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:24:21Z","timestamp":1768566261445,"version":"3.49.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Endoscopic eradication therapy using radiofrequency ablation (RFA) is considered an acceptable alternative to surveillance monitoring for Barrett\u2019s esophagus with low-grade dysplasia (LGD). This study aimed to estimate whether RFA for LGD is cost-effective and to determine which factors influence cost-effectiveness. A Markov model was developed to estimate the incremental cost per quality-adjusted life year (QALY) gained for RFA compared with endoscopic surveillance. An Australian longitudinal cohort study (PROBE-NET) provides the basis of the model. Replacing surveillance with RFA yields 10 fewer cases of HGD and 9 fewer esophageal adenocarcinoma (EAC)-related deaths per 1000 patients\u2019 treatment, given on average 0.192 QALYs at an additional cost of AU$9211 (\u20ac5689; US$6262) per patient (incremental cost-effectiveness ratio AU$47,815 per QALY). The model is sensitive to the rate of EAC from LGD health state, the utility values, and the number of RFA sessions. Hence, the incremental benefit ranges from 0.080 QALYs to 0.198 QALYs leading to uncertainty in the cost-effectiveness estimates. When the cancerous progression rate of LGD falls &amp;lt;0.47% per annum, the cost-effectiveness of RFA becomes questionable. RFA treatment of LGD provides significantly better clinical outcomes than surveillance. The additional cost of RFA is acceptable if the LGD to EAC rate is &amp;gt;0.47% per annum and no more than three RFA treatment sessions are provided. Accurate estimates of the risk of developing EAC in patients with LGD are needed to validate the analyses.<\/jats:p>","DOI":"10.1093\/dote\/doae095","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T11:28:23Z","timestamp":1730806103000},"source":"Crossref","is-referenced-by-count":1,"title":["Factors influencing the cost-effectiveness of radiofrequency ablation for Barrett\u2019s esophagus with low-grade dysplasia in Australia"],"prefix":"10.1093","volume":"38","author":[{"given":"Lauren","family":"Caush","sequence":"first","affiliation":[{"name":"The University of Notre Dame School of Medicine Department of Surgery, , Sydney,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9584-8431","authenticated-orcid":false,"given":"Jody","family":"Church","sequence":"additional","affiliation":[{"name":"University of Technology Sydney Faculty of Health, Centre for Health Economics Research and Evaluation, , Sydney,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Goodall","sequence":"additional","affiliation":[{"name":"University of Technology Sydney Faculty of Health, Centre for Health Economics Research and Evaluation, , Sydney,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reginald V","family":"Lord","sequence":"additional","affiliation":[{"name":"The University of Notre Dame School of Medicine Department of Surgery, , Sydney,","place":["Australia"]},{"name":"St. Vincent\u2019s Centre for Applied Medical Research Gastroesophageal Cancer Research Program, , Sydney,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,11,5]]},"reference":[{"issue":"13","key":"2025010911473225900_ref1","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/jnci\/djr203","article-title":"Risk of malignant progression in Barrett\u2019s esophagus patients: results from a large population-based study","volume":"103","author":"Bhat","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"2025010911473225900_ref2","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/jgh.12913","article-title":"Australian clinical practice guidelines for the diagnosis and management of Barrett\u2019s esophagus and early esophageal adenocarcinoma","volume":"30","author":"Whiteman","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"2025010911473225900_ref3","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1055\/s-0042-122140","article-title":"Endoscopic management of Barrett\u2019s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) position statement","volume":"49","author":"Weusten","year":"2017","journal-title":"Endoscopy"},{"issue":"2","key":"2025010911473225900_ref4","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1136\/gutjnl-2017-314135","article-title":"Revised British Society of Gastroenterology recommendation on the diagnosis and management of Barrett\u2019s oesophagus with low-grade dysplasia","volume":"67","author":"Pietro","year":"2018","journal-title":"Gut"},{"issue":"3","key":"2025010911473225900_ref5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.gie.2019.05.012","article-title":"ASGE guideline on screening and surveillance of Barrett\u2019s esophagus","volume":"90","author":"Qumseya","year":"2019","journal-title":"Gastrointest Endosc"},{"issue":"4","key":"2025010911473225900_ref6","doi-asserted-by":"crossref","first-page":"559","DOI":"10.14309\/ajg.0000000000001680","article-title":"Diagnosis and management of Barrett\u2019s esophagus: an updated ACG guideline","volume":"117","author":"Shaheen","year":"2022","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"2025010911473225900_ref7","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1001\/jama.2014.2511","article-title":"Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial","volume":"311","author":"Phoa","year":"2014","journal-title":"JAMA"},{"issue":"6","key":"2025010911473225900_ref8","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.gie.2014.01.009","article-title":"Incidence of esophageal adenocarcinoma in Barrett\u2019s esophagus with low-grade dysplasia: a systematic review and meta-analysis","volume":"79","author":"Singh","year":"2014","journal-title":"Gastrointest Endosc"},{"issue":"39","key":"2025010911473225900_ref9","doi-asserted-by":"crossref","first-page":"8831","DOI":"10.3748\/wjg.v22.i39.8831","article-title":"Progression from low-grade dysplasia to malignancy in patients with Barrett\u2019s esophagus diagnosed by two or more pathologists","volume":"22","author":"Moole","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"7","key":"2025010911473225900_ref10","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1053\/j.gastro.2009.02.062","article-title":"A cost-utility analysis of ablative therapy for Barrett\u2019s esophagus","volume":"136","author":"Inadomi","year":"2009","journal-title":"Gastroenterology"},{"issue":"3","key":"2025010911473225900_ref11","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1053\/j.gastro.2012.05.010","article-title":"The cost effectiveness of radiofrequency ablation for Barrett\u2019s esophagus","volume":"143","author":"Hur","year":"2012","journal-title":"Gastroenterology"},{"issue":"6","key":"2025010911473225900_ref12","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1136\/gutjnl-2014-307197","article-title":"Surveillance in patients with long-segment Barrett\u2019s oesophagus: a cost-effectiveness analysis","volume":"64","author":"Kastelein","year":"2015","journal-title":"Gut"},{"issue":"1","key":"2025010911473225900_ref13","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.gie.2016.12.001","article-title":"The cost-effectiveness of radiofrequency ablation for Barrett\u2019s esophagus with low-grade dysplasia: results from a randomized controlled trial (SURF trial)","volume":"86","author":"Phoa","year":"2017","journal-title":"Gastrointest Endosc"},{"issue":"5","key":"2025010911473225900_ref14","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1080\/03007995.2018.1552407","article-title":"A cost-effectiveness analysis of endoscopic eradication therapy for management of dysplasia arising in patients with Barrett\u2019s oesophagus in the United Kingdom","volume":"35","author":"Pollit","year":"2019","journal-title":"Cur Med Res Opin"},{"issue":"5","key":"2025010911473225900_ref15","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.clinthera.2023.04.007","article-title":"Cost-effectiveness analysis of radiofrequency ablation in patients with Barrett esophagus and high-grade dysplasia or low-grade dysplasia","volume":"45","author":"Federici","year":"2023","journal-title":"Clin Ther"},{"issue":"8","key":"2025010911473225900_ref16","doi-asserted-by":"crossref","first-page":"doaa119","DOI":"10.1093\/dote\/doaa119","article-title":"Clinical pathways and outcomes of patients with Barrett\u2019s esophagus in tertiary care settings: a prospective longitudinal cohort study in Australia, 2008\u20132016","volume":"34","author":"Na","year":"2020","journal-title":"Dis Esophagus"},{"issue":"8","key":"2025010911473225900_ref17","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jval.2018.01.017","article-title":"Comparing the ICERs in medicine reimbursement submissions to NICE and PBAC-does the presence of an explicit threshold affect the ICER proposed?","volume":"21","author":"Wang","year":"2018","journal-title":"Value Health"},{"issue":"22","key":"2025010911473225900_ref18","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMoa0808145","article-title":"Radiofrequency ablation in Barrett\u2019s esophagus with dysplasia","volume":"360","author":"Shaheen","year":"2009","journal-title":"N Engl J Med"},{"issue":"6","key":"2025010911473225900_ref19","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1136\/gutjnl-2020-322082","article-title":"Endoscopic radiofrequency ablation or surveillance in patients with Barrett\u2019s oesophagus with confirmed low-grade dysplasia: a multicentre randomised trial","volume":"70","author":"Barret","year":"2021","journal-title":"Gut"},{"key":"2025010911473225900_ref20","volume-title":"Department of Health and Aged Care. Medical Costs Finder [Internet]","author":"Australia","year":"2023"},{"issue":"1","key":"2025010911473225900_ref21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12876-018-0799-6","article-title":"Length of Barrett\u2019s segment predicts failure of eradication in radiofrequency ablation for Barrett\u2019s esophagus: a retrospective cohort study","volume":"18","author":"Luckett","year":"2018","journal-title":"BMC Gastroenterol"},{"issue":"5","key":"2025010911473225900_ref22","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1053\/j.gastro.2016.09.040","article-title":"Diagnosis and management of low-grade dysplasia in Barrett\u2019s esophagus: expert review from the clinical practice updates Committee of the American Gastroenterological Association","volume":"151","author":"Wani","year":"2016","journal-title":"Gastroenterology"},{"issue":"4","key":"2025010911473225900_ref23","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.gie.2017.10.011","article-title":"Endoscopic eradication therapy for patients with Barrett\u2019s esophagus-associated dysplasia and intramucosal cancer","volume":"87","author":"Wani","year":"2018","journal-title":"Gastrointest Endosc"},{"issue":"11","key":"2025010911473225900_ref24","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1111\/ans.18062","article-title":"Economic burden of complications and readmission following oesophageal cancer surgery","volume":"92","author":"Browning","year":"2022","journal-title":"ANZ J Surg"},{"issue":"15","key":"2025010911473225900_ref25","doi-asserted-by":"crossref","first-page":"9473","DOI":"10.3390\/ijerph19159473","article-title":"Cancer survivors\u2019 long-term health service costs in Queensland, Australia: results of a population-level data linkage study (cos-Q)","volume":"19","author":"Merollini","year":"2022","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"2025010911473225900_ref26","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.gie.2006.05.018","article-title":"Does cancer risk affect health-related quality of life in patients with Barrett\u2019s esophagus?","volume":"65","author":"Gerson","year":"2007","journal-title":"Gastrointest Endosc"},{"issue":"3","key":"2025010911473225900_ref27","first-page":"145","article-title":"Economic evaluation of endoscopic radiofrequency ablation for the treatment of dysplastic Barrett\u2019s esophagus in Spain","volume":"110","author":"Esteban","year":"2018","journal-title":"Rev Esp Enferm Dig"},{"issue":"8","key":"2025010911473225900_ref28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta10080","article-title":"Surveillance of Barrett\u2019s oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling","volume":"10","author":"Garside","year":"2006","journal-title":"Health Technol Assess"},{"issue":"2","key":"2025010911473225900_ref29","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1053\/j.gastro.2011.04.061","article-title":"Durability of radiofrequency ablation in Barrett\u2019s esophagus with dysplasia","volume":"141","author":"Shaheen","year":"2011","journal-title":"Gastroenterology"},{"issue":"28","key":"2025010911473225900_ref30","doi-asserted-by":"crossref","first-page":"9611","DOI":"10.3748\/wjg.v20.i28.9611","article-title":"Lifetime risk of esophageal adenocarcinoma in patients with Barrett\u2019s esophagus","volume":"20","author":"Gatenby","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"15","key":"2025010911473225900_ref31","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1056\/NEJMoa1103042","article-title":"Incidence of adenocarcinoma among patients with Barrett\u2019s esophagus","volume":"365","author":"Hvid-Jensen","year":"2011","journal-title":"N Engl J Med"},{"issue":"6","key":"2025010911473225900_ref32","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.gie.2016.02.009","article-title":"Risk of recurrence of Barrett\u2019s esophagus after successful endoscopic therapy","volume":"83","author":"Krishnamoorthi","year":"2016","journal-title":"Gastrointest Endosc"},{"issue":"7","key":"2025010911473225900_ref33","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/s41395-018-0090-z","article-title":"Higher rate of Barrett\u2019s detection in the first year after successful endoscopic therapy: meta-analysis","volume":"113","author":"Sawas","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"2025010911473225900_ref34","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1136\/gutjnl-2018-317513","article-title":"Timeline and location of recurrence following successful ablation in Barrett\u2019s oesophagus: an international multicentre study","volume":"68","author":"Sami","year":"2019","journal-title":"Gut"},{"issue":"11","key":"2025010911473225900_ref35","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1016\/j.cgh.2020.01.019","article-title":"Recurrence is rare following complete eradication of intestinal metaplasia in patients with Barrett\u2019s esophagus and peaks at 18 months","volume":"18","author":"Wani","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"2025010911473225900_ref36","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1053\/j.gastro.2011.06.055","article-title":"Risk factors for progression of low-grade dysplasia in patients with Barrett\u2019s esophagus","volume":"141","author":"Wani","year":"2011","journal-title":"Gastroenterology"},{"issue":"11","key":"2025010911473225900_ref37","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.cgh.2014.04.034","article-title":"Durability and predictors of successful radiofrequency ablation for Barrett\u2019s esophagus","volume":"12","author":"Pasricha","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"2025010911473225900_ref38","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1136\/gut.2003.033837","article-title":"What is the best management strategy for high grade dysplasia in Barrett\u2019s oesophagus? A cost effectiveness analysis","volume":"53","author":"Shaheen","year":"2004","journal-title":"Gut"},{"issue":"5","key":"2025010911473225900_ref39","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0016-5107(04)02167-4","article-title":"Cost-effectiveness of photodynamic therapy for high-grade dysplasia in Barrett\u2019s esophagus","volume":"60","author":"Vij","year":"2004","journal-title":"Gastrointest Endosc"},{"issue":"5","key":"2025010911473225900_ref40","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1055\/s-0029-1214612","article-title":"An economic analysis of endoscopic ablative therapy for management of nondysplastic Barrett\u2019s esophagus","volume":"41","author":"Das","year":"2009","journal-title":"Endoscopy"},{"issue":"1","key":"2025010911473225900_ref41","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/1753-6405.12005","article-title":"Australian health-related quality of life population norms derived from the SF-6D","volume":"37","author":"Norman","year":"2013","journal-title":"Aust N Z J Public Health"},{"issue":"3","key":"2025010911473225900_ref42","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.gie.2020.03.3756","article-title":"Radiofrequency ablation for low-grade dysplasia in Barrett\u2019s esophagus: long-term outcome of a randomized trial","volume":"92","author":"Pouw","year":"2020","journal-title":"Gastrointest Endosc"},{"key":"2025010911473225900_ref43","doi-asserted-by":"crossref","first-page":"801940","DOI":"10.3389\/fonc.2022.801940","article-title":"Efficacy and safety of radiofrequency ablation vs. endoscopic surveillance for Barrett\u2019s esophagus with low-grade dysplasia: meta-analysis of randomized controlled trials","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"}],"container-title":["Diseases of the Esophagus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/dote\/article-pdf\/38\/1\/doae095\/60420275\/doae095.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/dote\/article-pdf\/38\/1\/doae095\/60420275\/doae095.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T11:48:00Z","timestamp":1736423280000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/dote\/article\/doi\/10.1093\/dote\/doae095\/7875922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,5]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,7]]}},"URL":"https:\/\/doi.org\/10.1093\/dote\/doae095","relation":{},"ISSN":["1120-8694","1442-2050"],"issn-type":[{"value":"1120-8694","type":"print"},{"value":"1442-2050","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,11,5]]},"article-number":"doae095"}}